Pacira BioSciences, Inc. PCRX Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s fair value measurement with unobservable inputs reconciliation recurring basis asset value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s fair value measurement with unobservable inputs reconciliation recurring basis asset value?
- Pacira BioSciences, Inc. (PCRX) reported fair value measurement with unobservable inputs reconciliation recurring basis asset value of $10.25M in Q1 2026.
- How has Pacira BioSciences, Inc.'s fair value measurement with unobservable inputs reconciliation recurring basis asset value changed year-over-year?
- Pacira BioSciences, Inc.'s fair value measurement with unobservable inputs reconciliation recurring basis asset value decreased by 48.8% year-over-year, from $20M to $10.25M.
- What is the long-term trend for Pacira BioSciences, Inc.'s fair value measurement with unobservable inputs reconciliation recurring basis asset value?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s fair value measurement with unobservable inputs reconciliation recurring basis asset value has grown at a -4.3% compound annual growth rate (CAGR), from $12.8M to $10.25M.